In the latest close session, Adma Biologics (ADMA) was down 1.01% at $9.36. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, lost 0.65%.
Shares of the infectious disease drug developer witnessed a loss of 3.37% over the previous month, trailing the performance of the Medical sector with its loss of 0.36%, and the S&P 500's loss of 1.37%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release. On that day, Adma Biologics is projected to report earnings of $0.19 per share, which would represent year-over-year growth of 18.75%. At the same time, our most recent consensus estimate is projecting a revenue of $139.8 million, reflecting a 4.16% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.78 per share and a revenue of $536.82 million, representing changes of +30% and +5.22%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 12.17. This expresses a discount compared to the average Forward P/E of 20.54 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 169, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).